eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2012
vol. 37
 
Share:
Share:
abstract:

Clinical immunology
Changes in the serum interleukin-8 concentration after coronary by-pass surgery predict the occurrence of the post-cardiac injury syndrome

Maria Jaworska-Wilczyńska
,
Tomasz Hryniewiecki
,
Elżbieta Górska
,
Anna Stelmaszczyk-Emmel
,
Maria Wąsik

(Centr Eur J Immunol 2012; 37 (2): 154-158)
Online publish date: 2012/05/22
View full text Get citation
 
The post-cardiac injury syndrome (PCIS) is an important cardiologic problem associated with heart surgery. The pathogenesis of the PCIS is poorly understood, but immunologic mechanisms are considered to be the most important. Accordingly, we investigated the profiles of pro- and anti-inflammatory cytokines [interleukin (IL) 8, IL-1β, IL-6, IL-10, tumor necrosis factor a (TNF-α) and IL-12p70], before and after the heart surgery in patients with or without the PCIS, and in the healthy controls. The surgery caused significant increase of all the aforementioned cytokines; in addition, the pre-operative values were significantly higher than in control patients. Moreover, when the relative changes of the IL-8 concentration (e.g. ratios between the concentration after the surgery to the concentration before the surgery) were compared between PCIS-positive and PCIS-negative patients (PCIS-positive: mean ration 1.7 ±0.64 vs. PCIS-negative: 1.0 ±0.11) the difference between the indexes was statistically significant (p < 0.001). This is a novel finding suggesting that changes in the serum IL-8 concentration after the heart surgery may predict the occurrence of the PCIS.
keywords:

post-cardiac injury syndrome, PCIS, pericarditis, IL-8, heart surgery


Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.